Nitrosamines Analysis: Solutions for Risk Management and Analytical Testing from Experienced Industry Leaders

Whitepaper
Nitrosamines

Given stringent regulatory guidelines regarding the presence of nitrosamines, drug innovators and manufacturers must consider control of these impurities not only in the active pharmaceutical ingredient (API) chemical process, but also in their starting materials, solvents, and more. A plan for control early in development is critical to maintaining product quality and safety. Partnering with the right CDMO can help mitigate risk throughout the process.

Download our whitepaper for:

  • A definition/overview of nitrosamines
  • Insights into risk assessments for the potential formation of nitrosamines
  • Development and validation of analytical methodology
  • Analytical considerations